Vertex Pharmaceuticals (VRTX) ended the recent trading session at $470.10, demonstrating a -1.17% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily ...

Vertex Pharmaceuticals could have several important catalysts this year. The stock's long-term outlook seems highly ...

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $438.92, moving -2.36% from the previous trading session. This change lagged the S&P 500's daily gain of 0.26%. Elsewhere, the Dow ...

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares are trending on Thursday. Shares of the Massachusetts-based biotech company, which gained 4.31% during Wednesday's regular session, tapered down 0.21% ...

Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity Strategy” ...

Vertex Pharmaceutical (VRTX) stock gains as RBC Capital Markets upgrades the company to Outperform, citing a durable cystic ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $508.25, ...

Vertex Pharmaceuticals (VRTX) has been in focus after a series of analyst upgrades related to its cystic fibrosis franchise ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the best future stocks to buy for the long term. On January 12, ...

Shares of Vertex Pharmaceuticals Inc. VRTX shed 2.36% to $438.92 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.26% to ...

Learn more about whether Redwire Corporation or V2X, Inc. is a better investment based on AAII's A+ Investor grades, which ...